Cyfuse Biomedical K.K. (TYO:4892)

Market Cap	7.22B -9.1%
Revenue (ttm)	230.00M +325.9%
Net Income	-763.00M
EPS	-86.69
Shares Out	9.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	338,100
Average Volume	142,215
Open	716.00
Previous Close	709.00
Day's Range	697.00 - 738.00
52-Week Range	516.00 - 1,068.00
Beta	1.41
RSI	70.22
Earnings Date	May 14, 2026

About Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. develops, manufactures, and sells regenerative medicine-related products in Japan, Europe, and the United States. The company offers the Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bone, blood vessels, and nerves; regenova, a 3D software that creates 3D data where spheroids shall be mounted; and S-PIKE that develops 3D-structures from cells. It also provides the Human 3D Mini-Liver, an in vitro MASH model that recapitulates human liver functions and predicts efficacy of ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 23
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4892

Financial Performance

In 2025, Cyfuse Biomedical K.K.'s revenue was 230.00 million, an increase of 325.93% compared to the previous year's 54.00 million. Losses were -763.00 million, -12.50% less than in 2024.